Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 30.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,016 shares of the company’s stock after acquiring an additional 5,592 shares during the quarter. ProShare Advisors LLC’s holdings in Verve Therapeutics were worth $135,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. IFP Advisors Inc lifted its position in Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after acquiring an additional 8,237 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics during the fourth quarter worth approximately $50,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Verve Therapeutics during the fourth quarter worth approximately $101,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Verve Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock worth $101,000 after purchasing an additional 1,676 shares during the period. Finally, Arizona State Retirement System grew its position in Verve Therapeutics by 15.8% in the 4th quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock valued at $111,000 after buying an additional 2,669 shares during the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on VERV shares. Wall Street Zen raised Verve Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Royal Bank of Canada lowered their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, April 15th. HC Wainwright boosted their price target on Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, April 14th. Finally, Canaccord Genuity Group upped their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Verve Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

Verve Therapeutics Stock Up 7.9%

Shares of NASDAQ:VERV opened at $4.80 on Tuesday. The company has a market capitalization of $427.89 million, a P/E ratio of -1.95 and a beta of 1.82. Verve Therapeutics, Inc. has a 52-week low of $2.86 and a 52-week high of $9.31. The stock’s fifty day simple moving average is $4.47 and its 200-day simple moving average is $5.74.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. On average, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.